Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. executive Elliott Derick A., listed as EVP, Commercial, filed an initial Form 3 insider ownership report. This filing identifies him as a reporting officer of the company and, in the data shown, does not include any buy, sell, or derivative transactions.
Outset Medical Inc reports a Schedule 13G/A filing from The Vanguard Group disclosing zero shares beneficially owned.
The filing states Amount beneficially owned: 0 and Percent of class: 0%. It explains that on January 12, 2026 Vanguard completed an internal realignment and certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
Outset Medical, Inc. insider ownership has been updated in an amended Form 3. The amendment reflects indirect holdings by BML Investment Partners, L.P., including short put options tied to 617,500 and 110,000 shares of Outset Medical and 1,902,201 shares of common stock. The filing states these derivative securities were previously omitted due to a clerical error.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 2,842 shares of Common Stock at $3.35 per share in an open-market transaction. According to the footnote, this was a required “sell to cover” sale to satisfy tax withholding on 5,032 vesting RSU shares and was not a discretionary trade. Following the transaction, he directly owned 32,935 shares of Common Stock.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported an open-market sale of 3,361 shares of Common Stock at $3.35 per share to cover tax withholding on vested RSUs. After this tax-related sell-to-cover transaction, Trigg directly holds 102,342 shares and indirectly holds 41,666 shares through the Trigg 2002 Rev Trust and 584 shares through the Trigg Family Trust.
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,817 shares of common stock at $3.35 per share. After this transaction, he holds 39,988 shares of Outset Medical common stock.
According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of 4,384 shares underlying restricted stock units granted on March 15, 2021, July 24, 2023, January 12, 2024 and June 10, 2025. The filing states this was a “sell to cover” transaction and not a discretionary trade by Nash.
OM filing: a Form 144 notice reports proposed sale related to the settlement of 9,319 vested restricted stock units on 02/15/2026. The filing also lists three completed sales by Leslie Trigg totaling 15,709 shares across 01/07/2026, 01/20/2026, and 01/21/2026, with proceeds shown.
John Brottem reported sales of Common Stock via a Form 144 notice. The filing lists three dispositions: 244 shares on 01/07/2026, 9,314 shares on 01/20/2026, and 1,180 shares on 01/21/2026. The excerpt also shows the settlement of 5,032 vested restricted stock units on 02/15/2026 labeled as equity compensation.
Outset Medical, Inc. received an amended Schedule 13G/A from Durable Capital Partners reporting that it no longer beneficially owns any of the company’s common stock. The filing shows 0 shares beneficially owned and a 0.0% ownership of the class, with no voting or dispositive power reported.
The reporting person confirms its holdings are below 5% of the class and states that any securities referenced were acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Outset Medical.
Outset Medical, Inc. drew an updated ownership disclosure from institutional investors led by Health Sciences, LP. A group of related investment entities, including Health Sciences, LP, Health Sciences GP, LLC, Healthcare Growth Equity I GP, LLC, Partner Asset Management, LLC and Brian D. Grossman, reports beneficial ownership of 530,796 shares of Outset Medical common stock. Based on 18,153,090 shares outstanding as of November 6, 2025, this stake represents about 2.9% of the company’s outstanding shares, keeping the group below the 5% large-holder threshold. The reporting parties state that the securities were not acquired and are not held to change or influence control of Outset Medical.